Literature DB >> 16424527

Conjunctival epithelium improvement after systemic pilocarpine in patients with Sjogren's syndrome.

P Aragona1, R Di Pietro, R Spinella, M Mobrici.   

Abstract

AIM: To evaluate the effect of oral pilocarpine treatment on conjunctival epithelium of patients with Sjögren's syndrome (SS).
METHODS: 15 primary SS patients were included in this prospective, single masked, comparative study. Patients underwent oral pilocarpine treatment for 2 months and were studied before (T0) and after 1 month (T1), 2 months (T2), and 15 days after treatment suspension (T3). Systemic and ocular symptoms, tear film break up time (BUT), corneal fluorescein vital staining, Schirmer I test, tear basal secretion test, and conjunctival imprinting were performed. Student's t test and Mann-Whitney U test were used for statistics.
RESULTS: The conjunctival imprinting showed an increase of goblet cells number at T1 (1.6 (1.2) v 0.6 (0.7) at T0, p = 0.025) improving at T2 (5.1 (1.7); p<0.001 v T0 and T1). At T3 the number of goblet cells significantly decreased (1.9 (1.1); p<0.001 v T2). An improvement of dry mouth started at T1 and returned towards baseline values at T3. For ocular symptoms, burning and foreign body sensation were improved at T1 while ocular dryness improved at T2. BUT showed a statistically significant improvement at T2.
CONCLUSIONS: Oral pilocarpine induced an increase in goblet cells number and an amelioration of conjunctival epithelium not dependent on tear secretion.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16424527      PMCID: PMC1860166          DOI: 10.1136/bjo.2005.078865

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  32 in total

Review 1.  Current concepts on diagnosis, autoantibodies and therapy in Sjögren's syndrome.

Authors:  R Jonsson; H J Haga; T P Gordon
Journal:  Scand J Rheumatol       Date:  2000       Impact factor: 3.641

Review 2.  Use of muscarinic agonists in the treatment of Sjögren's syndrome.

Authors:  R I Fox; Y Konttinen; A Fisher
Journal:  Clin Immunol       Date:  2001-12       Impact factor: 3.969

Review 3.  Epithelial mucins of the ocular surface: structure, biosynthesis and function.

Authors:  P Argüeso; I K Gipson
Journal:  Exp Eye Res       Date:  2001-09       Impact factor: 3.467

Review 4.  Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group.

Authors:  C Vitali; S Bombardieri; R Jonsson; H M Moutsopoulos; E L Alexander; S E Carsons; T E Daniels; P C Fox; R I Fox; S S Kassan; S R Pillemer; N Talal; M H Weisman
Journal:  Ann Rheum Dis       Date:  2002-06       Impact factor: 19.103

Review 5.  Pathogenesis of Sjögren's syndrome.

Authors:  Kazuhiko Yamamoto
Journal:  Autoimmun Rev       Date:  2003-01       Impact factor: 9.754

6.  Muscarinic acetylcholine receptor antibodies as a new marker of dry eye Sjögren syndrome.

Authors:  S Bacman; A Berra; L Sterin-Borda; E Borda
Journal:  Invest Ophthalmol Vis Sci       Date:  2001-02       Impact factor: 4.799

7.  Presence of nerves and their receptors in mouse and human conjunctival goblet cells.

Authors:  Y Diebold; J D Ríos; R R Hodges; I Rawe; D A Dartt
Journal:  Invest Ophthalmol Vis Sci       Date:  2001-09       Impact factor: 4.799

Review 8.  Muscarinic acetylcholine receptors and airway diseases.

Authors:  Fiona R Coulson; Allison D Fryer
Journal:  Pharmacol Ther       Date:  2003-04       Impact factor: 12.310

9.  Sodium hyaluronate eye drops of different osmolarity for the treatment of dry eye in Sjögren's syndrome patients.

Authors:  P Aragona; G Di Stefano; F Ferreri; R Spinella; A Stilo
Journal:  Br J Ophthalmol       Date:  2002-08       Impact factor: 4.638

10.  Oral pilocarpine for the treatment of ocular symptoms in patients with Sjögren's syndrome: a randomised 12 week controlled study.

Authors:  N Tsifetaki; G Kitsos; C A Paschides; Y Alamanos; V Eftaxias; P V Voulgari; K Psilas; A A Drosos
Journal:  Ann Rheum Dis       Date:  2003-12       Impact factor: 19.103

View more
  6 in total

Review 1.  Topical and systemic medications for the treatment of primary Sjögren's syndrome.

Authors:  Manuel Ramos-Casals; Pilar Brito-Zerón; Antoni Sisó-Almirall; Xavier Bosch; Athanasios G Tzioufas
Journal:  Nat Rev Rheumatol       Date:  2012-05-01       Impact factor: 20.543

Review 2.  Unraveling the pathophysiology of Sjogren syndrome-associated dry eye disease.

Authors:  Cuong Q Nguyen; Ammon B Peck
Journal:  Ocul Surf       Date:  2009-01       Impact factor: 5.033

3.  [Sjögren's syndrome. Current aspects from a rheumatological point of view].

Authors:  C Tomiak; T Dörner
Journal:  Z Rheumatol       Date:  2006-10       Impact factor: 1.372

Review 4.  Efficacy and safety of topical and systemic medications: a systematic literature review informing the EULAR recommendations for the management of Sjögren's syndrome.

Authors:  Pilar Brito-Zerón; Soledad Retamozo; Belchin Kostov; Chiara Baldini; Hendrika Bootsma; Salvatore De Vita; Thomas Dörner; Jacques-Eric Gottenberg; Aike A Kruize; Thomas Mandl; Wan-Fai Ng; Raphaele Seror; Athanasios G Tzioufas; Claudio Vitali; Simon Bowman; Xavier Mariette; Manuel Ramos-Casals
Journal:  RMD Open       Date:  2019-10-28

Review 5.  A Narrative Review of Ocular Surface Disease Related to Anti-Glaucomatous Medications.

Authors:  Xiaoyu Zhou; Xinyue Zhang; Dengming Zhou; Yang Zhao; Xuanchu Duan
Journal:  Ophthalmol Ther       Date:  2022-08-09

Review 6.  Ophthalmologic Manifestations of Primary Sjögren's Syndrome.

Authors:  Anna Maria Roszkowska; Giovanni William Oliverio; Emanuela Aragona; Leandro Inferrera; Alice Antonella Severo; Federica Alessandrello; Rosaria Spinella; Elisa Imelde Postorino; Pasquale Aragona
Journal:  Genes (Basel)       Date:  2021-03-04       Impact factor: 4.096

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.